US2017189430A1PendingUtilityA1

Acyclic nucleoside phosphonate diesters

66
Assignee: UNIV CALIFORNIAPriority: Mar 15, 2013Filed: Mar 20, 2017Published: Jul 6, 2017
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Karl Y. HostetlerJames R. BeadleNadejda Valiaeva
A61P 31/20A61P 31/12A61P 35/02A61P 31/22A61P 31/18A61K 9/0034A61K 9/0014C07F 9/6512A61K 31/522C07F 9/65616C07F 9/65583C07F 9/6561A61K 31/675A61K 9/0031A61K 31/513A61K 31/685C07F 9/6524A61K 31/662C07F 9/40A61P 35/00Y02A50/30
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a proliferative disorder caused by human papilloma virus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The method of  claim 1 , wherein the proliferative disorder is cervical intraepithelial neoplasia. 
     
     
         3 . The method of  claim 1 , wherein the proliferative disorder is anal intraepithelial neoplasia. 
     
     
         4 . The method of  claim 1 , wherein the proliferative disorder is vulvar intraepithelial neoplasia. 
     
     
         5 . The method of  claim 1 , wherein the subject is a human. 
     
     
         6 . The method of  claim 2 , wherein the subject is a human. 
     
     
         7 . The method of  claim 3 , wherein the subject is a human. 
     
     
         8 . The method of  claim 4 , wherein the subject is a human. 
     
     
         9 . The method of  claim 1 , comprising topically administering the compound. 
     
     
         10 . The method of  claim 2 , comprising topically administering the compound. 
     
     
         11 . The method of  claim 3 , comprising topically administering the compound. 
     
     
         12 . The method of  claim 4 , comprising topically administering the compound. 
     
     
         13 . A method of treating cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a pharmaceutical composition which comprises (i) a compound of formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable carrier. 
       
     
     
         14 . The method of  claim 13  for treating cervical intraepithelial neoplasia. 
     
     
         15 . The method of  claim 13  for treating anal intraepithelial neoplasia. 
     
     
         16 . The method of  claim 13  for treating vulvar intraepithelial neoplasia. 
     
     
         17 . The method of  claim 13 , comprising topically administering the compound. 
     
     
         18 . The method of  claim 14 , comprising topically administering the compound. 
     
     
         19 . The method of  claim 15 , comprising topically administering the compound. 
     
     
         20 . The method of  claim 16 , comprising topically administering the compound.

Join the waitlist — get patent alerts

Track US2017189430A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.